Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience

Abstract

<jats:title>Abstract</jats:title><jats:p><jats:bold>Introduction</jats:bold>: Prostate carcinoma is the most frequent malign neoplasm among men with an ever-growing incidence rate. TMPRSS2-ERG fusion transcript leads to the androgen induction of ERG proto-oncogenes expression, representing a high presence of oncogenes alteration among prostate tumour cells.</jats:p><jats:p><jats:bold>Aim</jats:bold>: The aim of this research was to detect and evaluate theTMPRSS2-ERG fuse transcript in the tissues of patients with prostate cancer, and establish a base of material of these samples for further genetic examination.</jats:p><jats:p><jats:bold>Materials and methods</jats:bold>: The research was a prospective clinical study that involved and focused on random sampling of 101 patients (62 with prostate cancer-study group and 39 with benign changes in the prostate-control group). Real time PCR analysis for detection of the TMPRSS2-ERG fusion transcript in prostate tissue was performed and also data from the histopathology results of tissues were used, as well as data for the level of PSA (prostate-specific antigen) in blood.</jats:p><jats:p><jats:bold>Results</jats:bold>: TMPRSS2-ERG fusion transcript was detected in 20 out of 62 (32.2%) patients with prostate carcinoma and among no patients with benign changes whatsoever. There were no significant differences between patients with/without detected TMPRSS2-ERG fusion related to Gleason score. Among 50%, in the study group this score was greater than 7 per/for Median IQR=7 (6-8). Significant difference was recognized, related to the average value of PSA in favour of significantly higher value of PSA in the study group with prostate cancer, but there was also no significant difference between samples with prostate cancer who were with/without detected TMPRSS2-ERG fusion transcript related to PSA level.</jats:p><jats:p><jats:bold>Discussion</jats:bold>: The results from this research are in accordance with the values and results from analyses done in several research centres and oncological institutes.</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> The positive findings in small scale studies encourage the implementation of larger scale studies that will be enriched with results of genetic transcript in blood and urine and will define the positive diagnostic meaning of the TMPRSS-ERG fusion transcript.</jats:p>

The SARS-CoV-2 host cell membrane fusion protein TMPRSS2 is a tumor suppressor and its downregulation promotes antitumor immunity and immunotherapy response in lung adenocarcinoma

“…Previous studies of TMPRSS2 in cancer mainly focused on its oncogenic role in prostate cancer. [6][7][8] In this study, we focused on LUAD, considering that it is the most common histological type in lung cancer and that the lungs are the primary organ SARS-CoV-2 attacks. In contrast to its oncogenic role in prostate cancer, TMPRSS2 plays a tumor suppressive role in LUAD, as we have provided abundant evidence.…”

“…[2][3][4][5] Typically, the TMPRSS2-ERG gene fusion frequently occurs in prostate cancer and is associated with tumor progression. [6][7][8] In a recent study, 3 Katopodis et al revealed that TMPRSS2 was overexpressed in various cancers versus their normal tissues. In another study, 4 Kong et al explored TMPRSS2 expression in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).…”

The SARS-CoV-2 host cell membrane fusion protein TMPRSS2 is a tumor suppressor and its downregulation promotes antitumor immunity and immunotherapy response in lung adenocarcinoma

“…Previous studies of TMPRSS2 in cancer mainly focused on its oncogenic role in prostate cancer [6][7][8]. In this study, we focused on LUAD, considering that it is the most common histological type in lung cancer and that the lungs are the primary organ SARS-CoV-2 attacks.…”

“…Previous studies have demonstrated the association between TMPRSS2 and cancer [2][3][4][5]. Typically, the TMPRSS2-ERG gene fusion frequently occurs in prostate cancer and is associated with tumor progression [6][7][8]. In a recent study [3], Katopodis et al revealed that TMPRSS2 was overexpressed in various cancers versus their normal tissues.…”